(NASDAQ: DVAX) Dynavax Technologies's forecast annual revenue growth rate of -3.93% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 6.44%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.68%.
Dynavax Technologies's revenue in 2023 is $361,180,000.On average, 2 Wall Street analysts forecast DVAX's revenue for 2023 to be $30,744,693,173, with the lowest DVAX revenue forecast at $30,426,711,482, and the highest DVAX revenue forecast at $31,062,674,864. On average, 2 Wall Street analysts forecast DVAX's revenue for 2024 to be $35,237,800,319, with the lowest DVAX revenue forecast at $34,193,372,651, and the highest DVAX revenue forecast at $36,282,227,987.
In 2025, DVAX is forecast to generate $41,722,817,163 in revenue, with the lowest revenue forecast at $40,629,270,372 and the highest revenue forecast at $42,816,363,954.